Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.27 USD | -5.32% | -2.51% | 0.00% |
May. 08 | Earnings Flash (TSVT) 2SEVENTY BIO Reports Q1 Revenue $12.4M, vs. Street Est of $14.1M | MT |
May. 08 | Transcript : 2seventy bio, Inc., Q1 2024 Earnings Call, May 08, 2024 |
Financials (USD)
Sales 2024 * | 49.05M | Sales 2025 * | 103M | Capitalization | 232M |
---|---|---|---|---|---|
Net income 2024 * | -162M | Net income 2025 * | -47M | EV / Sales 2024 * | 4.73 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2.24 x |
P/E ratio 2024 * |
-1.44
x | P/E ratio 2025 * |
-5.35
x | Employees | 274 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.84% |
Latest transcript on 2seventy bio, Inc.
1 day | -5.32% | ||
1 week | -2.51% | ||
Current month | -6.36% | ||
1 month | +0.35% | ||
3 months | -28.36% | ||
6 months | +134.62% |
Managers | Title | Age | Since |
---|---|---|---|
Chip Baird
CEO | Chief Executive Officer | 52 | - |
Nick Leschly
CHM | Chairman | 51 | 21-05-03 |
Susan Abu-Absi
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Daniel Lynch
BRD | Director/Board Member | 65 | 21-10-14 |
Nick Leschly
CHM | Chairman | 51 | 21-05-03 |
Chip Baird
CEO | Chief Executive Officer | 52 | - |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
2.23% | 2 M€ | -25.75% | ||
0.03% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-28 | 4.27 | -5.32% | 295,036 |
24-05-24 | 4.51 | +2.50% | 380,787 |
24-05-23 | 4.4 | -3.30% | 398,152 |
24-05-22 | 4.55 | +3.88% | 330,867 |
24-05-21 | 4.38 | 0.00% | 378,501 |
Delayed Quote Nasdaq, May 28, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
0.00% | 232M | |
+54.05% | 63.85B | |
-2.02% | 41.83B | |
+40.01% | 40.47B | |
-10.22% | 27.17B | |
+13.42% | 26.52B | |
-21.60% | 18.69B | |
+2.89% | 12.73B | |
+22.40% | 12.11B | |
+27.49% | 12.07B |
- Stock Market
- Equities
- TSVT Stock